Flag of the European Union EU Clinical Trials Register Help

Clinical trials for MAF

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    16 result(s) found for: MAF. Displaying page 1 of 1.
    EudraCT Number: 2018-000618-39 Sponsor Protocol Number: Sym004-13 Start Date*: 2018-10-23
    Sponsor Name:Symphogen A/S
    Full Title: A Phase 2, Randomized, Open-Label, Multicenter, Three-Arm Trial of Sym004 versus each of its Component Monoclonal Antibodies, Futuximab and Modotuximab, in Patients with Chemotherapy-Refractory Met...
    Medical condition: Metastatic Colorectal Carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-021401-20 Sponsor Protocol Number: MAF/AGN/Facial/011 Start Date*: 2010-10-20
    Sponsor Name:Allergan Pharmaceuticals Ireland
    Full Title: A Multicenter, Randomised, Double-Blind Study to Evaluate the Efficacy of VISTABEL® (20 units) in the Treatment of Glabellar Lines, When Compared to BOCOUTURE® (30 units)
    Medical condition: Moderate to severe glabellar lines, as assessed by Facial Wrinkle Scale with Photonumeric Guide (FWS) at full contraction
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-012799-28 Sponsor Protocol Number: MAF-AGN-OPH-GLA-010 Start Date*: 2009-11-11
    Sponsor Name:Allergan
    Full Title: Estudio Piloto de tres meses, multicéntrico, enmascarado para el Investigador, para evaluar la eficacia y la seguridad de una combinación fija de Bimatoprost/Timolol versus Latanoprost en pacientes...
    Medical condition: Treatment-Naïve Patients with Open Angle Glaucoma at High Risk of Glaucomatous Progression. Pacientes Naïve con glaucoma de ángulo abierto con alto riesgo de progresión glaucomatosa.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2015-005448-32 Sponsor Protocol Number: DIUR-006 Start Date*: 2016-07-20
    Sponsor Name:Diurnal Ltd
    Full Title: A Phase III extension study of efficacy, safety and tolerability of Chronocort® in the treatment of congenital adrenal hyperplasia (CAH)
    Medical condition: Congenital adrenal hyperplasia (CAH); is generally due to 21-hydroxylase deficiency, is a disease of the adrenal cortex characterised by cortisol deficiency with or without aldosterone deficiency, ...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10010323 Congenital adrenal hyperplasia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) SE (Completed) DE (Completed) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-000144-21 Sponsor Protocol Number: DIUR-016-AI Start Date*: 2022-01-14
    Sponsor Name:Diurnal Limited
    Full Title: A Double-Blind, Double-Dummy, Two-Way Cross-Over, Randomised, Phase II Study of Efficacy, Safety and Tolerability of Modified-Release Hydrocortisones: Chronocort® Versus Plenadren®, in Adrenal Insu...
    Medical condition: Adrenal Insufficiency (AI)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10052381 Primary adrenal insufficiency PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-001634-17 Sponsor Protocol Number: MAF/ISS/OPH/GLA/035 Start Date*: 2013-10-30
    Sponsor Name:AZIENDA OSPEDALIERA S. PAOLO
    Full Title: LONG-TERM 24-HOUR INTRAOCULAR PRESSURE CONTROL AND PROGRESSION RATE OBTAINED WITH THE ASSOCIATION OF COMBIGAN IN THE MORNING AND GANFORT IN THE EVENING COMPARED WITH LATANOPROST IN HIGH RISK OPEN-A...
    Medical condition: Patients with glaucoma open angle or glaucoma exfoliative with high risknewly diagnosed and untreated.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-004663-22 Sponsor Protocol Number: NRL972-05/2007 (ETOH) Start Date*: 2008-04-14
    Sponsor Name:Norgine Limited
    Full Title: A multi-centre, open short term follow-up Phase II study to evaluate the clearance of NRL972 in patients undergoing alcohol withdrawal commencing in a controlled clinical setting.
    Medical condition: Alcoholic liver disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001627 Alcoholic liver disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2011-002392-41 Sponsor Protocol Number: Z102-009 Start Date*: 2012-03-28
    Sponsor Name:Zalicus, Inc.
    Full Title: A PHASE II, DOUBLE-BLIND, CONTROLLED, MULTI-CENTER, RANDOMIZED, LONG TERM SAFETY TRIAL OF Z102 AND PREDNISONE (5 MG OR 7.5 MG) IN PATIENTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS
    Medical condition: Treatment of patients with moderate to severe rheumatoid arthritis (RA)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021428 - Immune system disorders 10039075 Rheumatoid arthritis and associated conditions HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-000923-32 Sponsor Protocol Number: OSM104972 Start Date*: 2008-08-13
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A randomised, double-blind, placebo-controlled, Bayesian adaptive dose finding study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and repeat intravenous ...
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039073 Rheumatoid arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-006227-38 Sponsor Protocol Number: 11.017 Start Date*: 2012-05-01
    Sponsor Name:Ove B. Schaffalitzky de Muckadell
    Full Title: “Assessment of fibrotic liver disease in a medical admission ward and intervention with losartan as antifibrotic therapy in patients with alcoholic liverdisease”
    Medical condition: Fibrotic alcoholic liver disease is in early stages often completely asymptomatic. Fully developed cirrhosis affect a wide range of physiological conditions. Eksamples are portal hypertension and f...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10019805 - Hepatobiliary disorders 10001627 Alcoholic liver disease PT
    14.1 10019805 - Hepatobiliary disorders 10001626 Alcoholic liver damage, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-023900-29 Sponsor Protocol Number: MAF-AGN-OPH-RET-004 Start Date*: 2011-08-23
    Sponsor Name:Allergan Pharmaceuticals Ireland
    Full Title: A 12-Month, Multicentre, Randomised, Parallel Group Study to Compare the Efficacy and Safety of Ozurdex® Versus Lucentis® in Patients with Branch Retinal Vein Occlusion
    Medical condition: Macula oedema secondary to branch retinal vein occlusion
    Disease: Version SOC Term Classification Code Term Level
    17.0 10015919 - Eye disorders 10025415 Macular oedema PT
    17.0 10015919 - Eye disorders 10038907 Retinal vein occlusion PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-002050-36 Sponsor Protocol Number: P160935J Start Date*: Information not available in EudraCT
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: Personalised pharmacological approach to the tapering of corticosteroid doses in systemic lupus patients treated with prednisone
    Medical condition: Systemic lupus erythematosus
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-006023-33 Sponsor Protocol Number: SIMFIB Start Date*: 2021-10-26
    Sponsor Name:Institut d’Investigacions Biomèdiques August Pi i Sunyer
    Full Title: Efficacy of simvastatin reducing liver fibrosis in patients with advanced fibrosis due to alcohol: a randomized, double-blind, placebo-controlled clinical trial.
    Medical condition: reduction of liver fibrosis in patients with advanced fibrosis due to alcohol
    Disease: Version SOC Term Classification Code Term Level
    20.1 10019805 - Hepatobiliary disorders 10001627 Alcoholic liver disease PT
    20.0 10019805 - Hepatobiliary disorders 10019668 Hepatic fibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-001220-30 Sponsor Protocol Number: EGF117165 Start Date*: 2014-07-25
    Sponsor Name:GlaxoSmithKline, S.A.
    Full Title: An Open-Label, Phase II, Study to Evaluate Biomarkers Associated with Response to Subsequent Therapies in Subjects with HER2-Positive Metastatic Breast Cancer Receiving Treatment with Trastuzumab i...
    Medical condition: HER2 positive Metastatic Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Prematurely Ended) IT (Completed) AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-001969-33 Sponsor Protocol Number: TAK-242-2001 Start Date*: 2020-05-28
    Sponsor Name:Akaza Bioscience Limited
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Proof-of-Concept, Phase 2a Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous TAK-242 in Subj...
    Medical condition: Acute Alcoholic Hepatitis Causing Decompensation of Alcohol related Cirrhosis and Acute-on-Chronic Liver Failure
    Disease: Version SOC Term Classification Code Term Level
    20.1 10019805 - Hepatobiliary disorders 10001627 Alcoholic liver disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Prematurely Ended) HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-003006-25 Sponsor Protocol Number: SPD489-323 Start Date*: 2012-02-02
    Sponsor Name:Shire Development Inc.
    Full Title: The SPD489-323, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexible Dose Titration, Efficacy and Safety Study of SPD489 in Combination with an Antidepressan...
    Medical condition: Major Depressive Disorder
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) PL (Completed) CZ (Completed) BE (Completed) EE (Completed) FI (Completed) IT (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 07 22:41:06 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA